Metagenomi, INC 8-K filings

Metagenomi Therapeutics announced second quarter 2026 financial results and business updates, highlighting progress on its MGX-001 hemophilia A program with an IND submission planned for Q4 2026.

Metagenomi Therapeutics announced full-year 2025 financial results and significant progress in its lead hemophilia A program, MGX-001, targeting clinical trials in 2027.

Metagenomi, Inc. rebrands to Metagenomi Therapeutics, Inc., highlighting its strategic focus on lead gene-editing programs and extending its cash runway into Q4 2027.

Metagenomi announced Q3 2025 financial results, strategic pipeline reprioritization, a 25% workforce reduction, and new leadership, extending its cash runway into Q4 2027.

Metagenomi secured a non-exclusive license for Acuitas LNP technology for a single target while simultaneously terminating its agreement with Affini-T Therapeutics due to Affini-T's insolvency.

Metagenomi, a precision genetic medicines company, reported its second quarter 2025 financial results and provided updates on its gene editing programs, including progress on MGX-001 for hemophilia A and its collaboration with Ionis.

Metagenomi, Inc. announced the results of its 2025 annual meeting of stockholders, where Willard H. Dere, M.D. was elected as a Class I Director and PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2025.

Metagenomi showcases advancements in gene editing technologies, including compact nucleases and CRISPR-associated transposases (CAST), at the ASGCT Annual Meeting.

Metagenomi announces encouraging 19-month durability data from its hemophilia A program's non-human primate study, along with a solid cash position to support operations into 2027.

Metagenomi, Inc. has entered into an agreement with Jefferies LLC to sell up to $75 million of its common stock through an at-the-market offering.

Metagenomi announces advancements in its hemophilia A program, progress in cardiometabolic indications through the Ionis collaboration, and a strong cash position to support operations into 2027.

Metagenomi, Inc. expands its board of directors with the appointment of Eric Bjerkholt and updates its investor presentation, highlighting progress in its gene editing programs.

Metagenomi reports sustained Factor VIII activity in non-human primates for over 16 months, with its lead candidate, MGX-001, showing higher activity than wild-type FVIII.

Metagenomi announced its Q3 2024 financial results and provided a business update, highlighting progress in its hemophilia A program and novel gene editing technologies.

Metagenomi's preclinical study of its hemophilia A gene editing therapy, MGX-001, shows durable Factor VIII activity levels in non-human primates over twelve months, supporting its potential as a curative treatment.

Metagenomi announced its second quarter 2024 financial results and provided a business update, highlighting the declaration of a lead development candidate for hemophilia A and a strong cash position.

Metagenomi reported its Q1 2024 financial results, highlighted by a strong cash position and advancements in its gene editing programs, including regaining full rights to key technologies.

Metagenomi has terminated its collaboration with Moderna, regaining full rights to its gene editing technologies, and reports a strong cash position of $327.4 million as of March 31, 2024.

Metagenomi reported its full year 2023 financial results and provided business updates, showcasing advancements in its gene editing technology and progress in its Hemophilia A program.

Metagenomi, Inc. has filed an amended and restated certificate of incorporation and bylaws in connection with its initial public offering.